Guangdi Li
- Infectious Diseases top 0.5%
- Molecular Biology top 5%
- Epidemiology top 2%
- Immunology top 5%
- Computational Theory and Mathematics top 1%
- Co-authors
- Erik De ClercqRichard J. WhitleyRolf HilgenfeldYali WangAnne–Mieke VandammeMiao MiaoKristof TheysHaizhen Zhu
- Topics
- Hepatitis B Virus Studies (28 papers)Hepatitis C virus research (23 papers)HIV/AIDS drug development and treatment (18 papers)
- Partner nations
- ChinaBelgiumUnited States
In The Last Decade
Guangdi Li
95 papers receiving 5.0k citations
Hit Papers
Peers
Comparison fields: 5 of 166
- Infectious Diseases 2.3k
- Molecular Biology 1.4k
- Epidemiology 1.2k
- Immunology 650
- Computational Theory and Mathematics 511
Countries citing papers authored by Guangdi Li
This map shows the geographic impact of Guangdi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangdi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangdi Li more than expected).
Fields of papers citing papers by Guangdi Li
This network shows the impact of papers produced by Guangdi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangdi Li. The network helps show where Guangdi Li may publish in the future.
Co-authorship network of co-authors of Guangdi Li
This figure shows the co-authorship network connecting the top 25 collaborators of Guangdi Li. A scholar is included among the top collaborators of Guangdi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangdi Li. Guangdi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 4 | |
| 4 | 2 | |
| 5 | 11 | |
| 6 | Therapeutic strategies for COVID-19: progress and lessons learnedbreakdown → | 341 |
| 7 | 10 | |
| 8 | 5 | |
| 9 | 6 | |
| 10 | 7 | |
| 11 | 40 | |
| 12 | 21 | |
| 13 | 33 | |
| 14 | 7 | |
| 15 | 76 | |
| 16 | 84 | |
| 17 | 30 | |
| 18 | 116 | |
| 19 | 134 | |
| 20 | 56 |
About Guangdi Li
Guangdi Li is a scholar working on Virology, Hepatology and Infectious Diseases, having authored 97 papers that have together received 5.1k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (28 papers), Hepatitis C virus research (23 papers) and HIV/AIDS drug development and treatment (18 papers). The work is most often cited by research in Infectious Diseases (2.3k citations), Virology (487 citations) and Hepatology (472 citations). Guangdi Li has collaborated with scholars based in China, Belgium and United States. Frequent co-authors include Erik De Clercq, Richard J. Whitley, Rolf Hilgenfeld, Yali Wang, Anne–Mieke Vandamme, Miao Miao, Kristof Theys, Haizhen Zhu, Supinya Piampongsant and Binbin Xue. Their work appears in journals such as Nature Communications, The Journal of Immunology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.